Articles > Popular publications > PR Newswire press releases > January-March 2007 > Tuesday, January 16

Article: BioMarin Announces Positive Results From Phase 3 Diet Study of Phenoptin for PKU.

Article from:
PR Newswire
Article date:
January 16, 2007
Copyright

Phenoptin Significantly Increases Phenylalanine Tolerance in BH4-Responsive Patients; All Pre-Specified Endpoints Met

Conference Call to be Held Today at 12:00 p.m. EST

NOVATO, Calif., Jan. 16 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the Phase 3 diet study of Phenoptin(TM) (sapropterin dihydrochloride), in combination with diet, in 4-12 year old patients. Phenoptin is an investigational oral small molecule, being developed in partnership with Merck Serono, for the treatment of patients with phenylketonuria (PKU), who have elevated phenylalanine (Phe) levels. The results show that ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Merck Serono Announces Positive Results From Phase III Diet Study ...
PR Newswire;  January 16, 2007 ;     700+ words ... ... controlled study were met. Phenoptin treatment caused a significant ... addition, the data showed that Phenoptin was well tolerated in younger ... Professor of Pediatrics at Harvard Medical School and Senior Associate in Medicine ... PKU patients. If approved, Phenoptin offers patients who ...

Article: Development of Phenoptin accelerated.
Biotech Week;  December 17, 2003 ;     700+ words ... ... announced plans to begin clinical trials with Phenoptin, an enzyme cofactor that is a second ... in the developed world. If approved, Phenoptin could become the first prescription drug ... for the manufacturing and supply of Phenoptin. "Phenoptin represents an outstanding ...

Article: BIOMARIN ACCELERATES DEVELOPMENT OF PHENOPTIN FOR PKU.
Biotech Business;  January 1, 2004 ;     700+ words ... ... has initiated clinical trials with Phenoptin(TM), an enzyme cofactor that is a ... in the developed world. If approved, Phenoptin could become the first prescription drug ... for the manufacturing and supply of Phenoptin. "Phenoptin represents an outstanding ...

Article: BioMarin Accelerates Development of Phenoptin, a Novel ...
PR Newswire;  November 20, 2003 ;     700+ words ... ... announced plans to begin clinical trials with Phenoptin(TM), an enzyme cofactor that is a ... in the developed world. If approved, Phenoptin could become the first prescription drug ... for the manufacturing and supply of Phenoptin. "Phenoptin represents an outstanding ...

Article: BioMarin's Shares Move On Phenoptin Phase III ...
BIOWORLD Today;  March 17, 2006 ;     700+ words ... ... Pharmaceutical Inc. surged Thursday on news that Phenoptin hit statistical significance in its Phase ... product entered the study in April. Phenoptin (sapropterin dihydrochloride) met all ... pushed aside by the Phase III results for Phenoptin. The PKU drug could become the only ...

Article: BioMarin Initiates Phase 3 Clinical Trial of Phenoptin for ...
PR Newswire;  April 7, 2005 ;     700+ words ... ... patient in its Phase 3 clinical trial of Phenoptin(TM) (sapropterin hydrochloride ... at which we have been able to advance Phenoptin for PKU into the clinic, moving it from ... hydrochloride, the active ingredient in Phenoptin." The Phase 3, double-blind, placebo ...

Article: BioMarin to Initiate a Phase 3 Clinical Trial of Phenoptin ...
PR Newswire;  November 30, 2004 ;     700+ words ... ... controlled Phase 3 clinical trial of Phenoptin(TM) (sapropterin hydrochloride ... phenylalanine (Phe) level in patients receiving Phenoptin compared to patients receiving placebo ... plan with the FDA, we can now advance Phenoptin into late-stage clinical development ...

Article: BioMarin Receives FDA Fast Track Designation for Phenoptin ...
PR Newswire;  January 25, 2006 ;     700+ words ... ... granted Fast Track designation for Phenoptin(TM) (sapropterin dihydrochloride) for phenylketonuria (PKU). Phenoptin, an investigational oral small molecule ... the agency in our effort to develop Phenoptin as the first drug therapy for its ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives